Julia Thornton Snider

1.5k total citations
68 papers, 998 citations indexed

About

Julia Thornton Snider is a scholar working on Oncology, Pathology and Forensic Medicine and Economics and Econometrics. According to data from OpenAlex, Julia Thornton Snider has authored 68 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 20 papers in Pathology and Forensic Medicine and 18 papers in Economics and Econometrics. Recurrent topics in Julia Thornton Snider's work include CAR-T cell therapy research (24 papers), Lymphoma Diagnosis and Treatment (20 papers) and Health Systems, Economic Evaluations, Quality of Life (11 papers). Julia Thornton Snider is often cited by papers focused on CAR-T cell therapy research (24 papers), Lymphoma Diagnosis and Treatment (20 papers) and Health Systems, Economic Evaluations, Quality of Life (11 papers). Julia Thornton Snider collaborates with scholars based in United States, United Kingdom and Canada. Julia Thornton Snider's co-authors include Darius Lakdawalla, Dana P. Goldman, Mark T. Linthicum, Refaat Hegazi, John A. Romley, Anupam B. Jena, Anik R. Patel, Tomas Philipson, Frederick L. Locke and Katharine Batt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Julia Thornton Snider

68 papers receiving 955 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julia Thornton Snider United States 18 323 258 195 150 140 68 998
Marc H. Hemmelder Netherlands 19 104 0.3× 56 0.2× 205 1.1× 148 1.0× 45 0.3× 71 1.2k
Matteo Franchi Italy 18 91 0.3× 312 1.2× 38 0.2× 72 0.5× 39 0.3× 92 1.1k
Évelyne Liuu France 14 368 1.1× 184 0.7× 35 0.2× 88 0.6× 20 0.1× 32 797
Max Brosa Spain 18 303 0.9× 56 0.2× 54 0.3× 138 0.9× 22 0.2× 91 1.2k
Douglas L. Nguyen United States 22 157 0.5× 318 1.2× 169 0.9× 70 0.5× 26 0.2× 72 1.4k
Soon‐Ae Shin South Korea 15 145 0.4× 230 0.9× 52 0.3× 26 0.2× 60 0.4× 27 922
J. Oristrell Spain 17 90 0.3× 34 0.1× 77 0.4× 155 1.0× 164 1.2× 38 1.2k
A. Doussau France 14 137 0.4× 111 0.4× 27 0.1× 56 0.4× 44 0.3× 30 619
June‐Ho Kim United States 16 90 0.3× 89 0.3× 37 0.2× 78 0.5× 76 0.5× 29 967
Wing C. Chan Canada 18 120 0.4× 124 0.5× 17 0.1× 61 0.4× 54 0.4× 78 1.1k

Countries citing papers authored by Julia Thornton Snider

Since Specialization
Citations

This map shows the geographic impact of Julia Thornton Snider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Thornton Snider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Thornton Snider more than expected).

Fields of papers citing papers by Julia Thornton Snider

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Thornton Snider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Thornton Snider. The network helps show where Julia Thornton Snider may publish in the future.

Co-authorship network of co-authors of Julia Thornton Snider

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Thornton Snider. A scholar is included among the top collaborators of Julia Thornton Snider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Thornton Snider. Julia Thornton Snider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hoogland, Aasha I., Xiaoyin Li, Laura B. Oswald, et al.. (2024). Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene Ciloleucel. Transplantation and Cellular Therapy. 31(3). 157.e1–157.e13. 2 indexed citations
3.
Snider, Julia Thornton, et al.. (2023). Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma. Future Oncology. 19(22). 1535–1547. 1 indexed citations
4.
5.
Kersten, Marie José, Ruchit Shah, Caitlyn T. Solem, et al.. (2023). Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma. Transplantation and Cellular Therapy. 29(5). 335.e1–335.e8. 3 indexed citations
6.
Ghione, Paola, M. Lia Palomba, Anik R. Patel, et al.. (2022). Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 140(8). 851–860. 35 indexed citations
7.
Hatswell, Anthony J., et al.. (2022). Approaches to Selecting “Time Zero” in External Control Arms with Multiple Potential Entry Points: A Simulation Study of 8 Approaches. Medical Decision Making. 42(7). 893–905. 10 indexed citations
8.
Snider, Julia Thornton, et al.. (2022). Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care. Advances in Therapy. 39(8). 3560–3577. 15 indexed citations
9.
Kilgore, Karl M., et al.. (2021). Burden of Illness and Outcomes in Second-Line Large B-Cell Lymphoma Treatment: Real-World Analysis of Medicare Beneficiaries. Future Oncology. 17(35). 4837–4847. 3 indexed citations
10.
Snider, Julia Thornton, Jeffrey Sullivan, Michael K. Hansen, et al.. (2019). Lifetime benefits of early detection and treatment of diabetic kidney disease. PLoS ONE. 14(5). e0217487–e0217487. 31 indexed citations
11.
Snider, Julia Thornton, et al.. (2018). The Option Value of Innovative Treatments for Metastatic Melanoma. Forum for Health Economics & Policy. 21(1). 14 indexed citations
12.
Snider, Julia Thornton, Yanni Hao, Pinar Karaca‐Mandic, et al.. (2017). The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom. Blood. 130. 1330–1330. 4 indexed citations
13.
Snider, Julia Thornton, et al.. (2017). The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.. PubMed. 23(10). e340–e346. 15 indexed citations
14.
Yin, Wesley, et al.. (2017). Association Between Breast Cancer Disease Progression and Workplace Productivity in the United States. Journal of Occupational and Environmental Medicine. 59(2). 198–204. 18 indexed citations
15.
Philipson, Tomas, Mark T. Linthicum, & Julia Thornton Snider. (2014). Tutorial on Health Economics and Outcomes Research in Nutrition. Journal of Parenteral and Enteral Nutrition. 38(2S). 5S–16S. 6 indexed citations
16.
Lakdawalla, Darius, Julia Thornton Snider, Mark T. Linthicum, et al.. (2014). Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital?. Forum for Health Economics & Policy. 17(2). 131–151. 8 indexed citations
17.
Bognar, Katalin, et al.. (2013). Clinical Outcomes Associated With Rates of Sulfonylurea Use Among Physicians. The American Journal of Managed Care. 19. 2 indexed citations
18.
Snider, Julia Thornton, et al.. (2012). The Disability Burden of COPD. COPD Journal of Chronic Obstructive Pulmonary Disease. 9(5). 513–521. 48 indexed citations
19.
Snider, Julia Thornton, John A. Romley, William B. Vogt, & Tomas Philipson. (2012). The Option Value of Innovation. Forum for Health Economics & Policy. 15(1). 14 indexed citations
20.
Holmes, Thomas J. & Julia Thornton Snider. (2011). A Theory of Outsourcing and Wage Decline. American Economic Journal Microeconomics. 3(2). 38–59. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marc H. Hemmelder Breakdown of academic impact, for papers by Matteo Franchi Breakdown of academic impact, for papers by Évelyne Liuu Breakdown of academic impact, for papers by Max Brosa Breakdown of academic impact, for papers by Douglas L. Nguyen Breakdown of academic impact, for papers by Soon‐Ae Shin Breakdown of academic impact, for papers by J. Oristrell Breakdown of academic impact, for papers by A. Doussau Breakdown of academic impact, for papers by June‐Ho Kim Breakdown of academic impact, for papers by Wing C. Chan
Rankless by CCL
2026